Bioventix PLC (LON:BVXP – Get Free Report) insider Peter John Harrison acquired 875 shares of the stock in a transaction on Tuesday, November 4th. The shares were bought at an average price of GBX 2,220 per share, with a total value of £19,425.
Bioventix Trading Down 1.4%
Bioventix stock opened at GBX 2,170 on Friday. Bioventix PLC has a 12 month low of GBX 1,750 and a 12 month high of GBX 4,000. The business’s fifty day simple moving average is GBX 2,350.35 and its two-hundred day simple moving average is GBX 2,566.17. The company has a market capitalization of £113.38 million, a price-to-earnings ratio of 15.14 and a beta of 0.35.
Bioventix (LON:BVXP – Get Free Report) last announced its quarterly earnings results on Monday, October 27th. The biotechnology company reported GBX 145.27 earnings per share (EPS) for the quarter. Bioventix had a net margin of 59.51% and a return on equity of 69.09%. On average, equities research analysts predict that Bioventix PLC will post 166.3066955 EPS for the current year.
Bioventix Company Profile
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Further Reading
- Five stocks we like better than Bioventix
- How to Invest in Biotech Stocks
- CAVA Stock Looking for Direction After Earnings Miss
- What is the Nasdaq? Complete Overview with History
- 3 Small AI Stocks Ready to Explode (All Under $20)
- How to Use the MarketBeat Dividend Calculator
- After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms
Receive News & Ratings for Bioventix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix and related companies with MarketBeat.com's FREE daily email newsletter.
